The emergence of nitroxyl (HNO) as a pharmacological agent.
Once a virtually unknown nitrogen oxide, nitroxyl (HNO) has emerged as a potential pharmacological agent. Recent advances in the understanding of the chemistry of HNO has led to the an understanding of HNO biochemistry which is vastly different from the known chemistry and biochemistry of nitric oxide (NO), the one-electron oxidation product of HNO. The cardiovascular roles of NO have been extensively studied, as NO is a key modulator of vascular tone and is involved in a number of vascular related pathologies. HNO displays unique cardiovascular properties and has been shown to have positive lusitropic and ionotropic effects in failing hearts without a chronotropic effect. Additionally, HNO causes a release of CGRP and modulates calcium channels such as ryanodine receptors. HNO has shown beneficial effects in ischemia reperfusion injury, as HNO treatment before ischemia-reperfusion reduces infarct size. In addition to the cardiovascular effects observed, HNO has shown initial promise in the realm of cancer therapy. HNO has been demonstrated to inhibit GAPDH, a key glycolytic enzyme. Due to the Warburg effect, inhibiting glycolysis is an attractive target for inhibiting tumor proliferation. Indeed, HNO has recently been shown to inhibit tumor proliferation in mouse xenografts. Additionally, HNO inhibits tumor angiogenesis and induces cancer cell apoptosis. The effects seen with HNO donors are quite different from NO donors and in some cases are opposite. The chemical nature of HNO explains how HNO and NO, although closely chemically related, act so differently in biochemical systems. This also gives insight into the potential molecular motifs that may be reactive towards HNO and opens up a novel field of pharmacological development.
Switzer
Christopher H
CH
Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room B3-B35, Bethesda, MD 20892, USA.
Flores-Santana
Wilmarie
W
Mancardi
Daniele
D
Donzelli
Sonia
S
Basudhar
Debashree
D
Ridnour
Lisa A
LA
Miranda
Katrina M
KM
Fukuto
Jon M
JM
Paolocci
Nazareno
N
Wink
David A
DA
D000818:Animals; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008954:Models, Biological; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy; D009569:Nitric Oxide / Q000494:pharmacology / Q000627:therapeutic use; D009589:Nitrogen Oxides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
D009589:Nitrogen Oxides; D009569:Nitric Oxide; C039900:nitroxyl